

Online supplementary Table S2. Comparison with other asthma statements				
	ERS	GINA	NICE	NHBLI- NAEPP
Care Setting	Primary and Secondary Care	Primary and Secondary Care	Primary and Secondary Care	Primary and Secondary Care
Patient or Public Partners	Yes	Yes	Yes	Yes. Specific Focus Groups and Interviews
Panel Composition	European Lung Foundation GPs Respiratory Physicians Respiratory Nurse	Specialists GP	Public Health Consultant GPs Asthma Nurse Paediatricians Pharmacist Physiologist Respiratory Physician	Paediatric and Adults Allergists/Pulmonologists Internal, Family and Emergency Medicine Health Policy Experts
Frequency	First publication	Twice-Yearly Reviews	As Needed	Not Applicable
Methodology	PICO Framework Systematic literature reviews Meta-analyses Risk of bias assessment with QUADAS Checklist GRADE approach for assessing the quality of the evidence Evidence to Decision Framework	Literature Search including previously conducted Systematic Reviews Individual and Committee Evaluation (Relevance, Quality, Reliability)	Systematic literature reviews Meta-analyses Risk of bias assessment with QUADAS Checklist GRADE approach for assessing the quality of the evidence Evidence to Decision Framework	Systematic literature reviews, Meta-analyses GRADE approach for assessing the quality of the evidence Evidence to Decision Framework
Patient Population	Adults (>16 years old) with suspected asthma	All ages with suspected asthma	All ages with suspected asthma	All ages with suspected asthma
Diagnostic Tests Evaluated or Included in Statement	<ul style="list-style-type: none"> ●Spirometry (FEV1/FVC<LLN, 75%) ●Peak Flow Variability ●FeNO ●Bloods Eosinophils 	<ul style="list-style-type: none"> ●Symptoms FEV1/FVC<LLN, <u>usually</u> >0.75-0.80 in adults) 	<ul style="list-style-type: none"> ●Symptoms alone ●History of Atopy ●Exercise induced symptoms ●Effects of Drugs: beta-blockers, aspirin, NSAIDs 	<ul style="list-style-type: none"> ●FeNO

	<ul style="list-style-type: none"> ●Total IgE ●Combination FeNO, Blood Eosinophils, IgE ●Bronchial Challenge ●Bronchodilator Reversibility ●Airway Resistance sGaw and RV/TLC 	<ul style="list-style-type: none"> ●Bronchodilator Reversibility ●Peak Flow ●FeNO evaluated ●Improvement in FEV1 after ICS (4-weeks) ●FEV1 variability between visits ●Blood Eosinophils for eligibility of biologic treatment 	<ul style="list-style-type: none"> ●Occupational Asthma ●Spirometry/flow volume ●Bronchodilator Reversibility ●Peak Flow Variability ●Skin Prick Testing ●Total and Specific IgE ●FeNO ●Blood Eosinophils ●Bronchial Challenges inc. Exercise Challenge 	
Therapies Evaluated	No	Yes	Yes	Yes
Independent Peer Reviewed	Yes	Sent out for open consultation.	Sent out for open consultation.	Yes Sent out for open consultation as well. Reviewed by NIH and U.S. Department of Health and Human Services
Intended Applicability	Global	Global	National Health Service (NHS), UK	U.S.
Cost-Effectiveness Evaluated	No	No	Yes	No